Michael Paukshto, PhD, CTO and co-founder of Fibralign Corporation, was awarded the 2014 Best New Investigator Award at the 11th Biennial NLN International Conference.
Fibralign has developed and established an end-to-end manufacturing system for production of its BioBridge Collagen Matrix in its GMP facility located in Union City, California.
Multi-site clinical study to evaluate BioBridge® as prophylactic treatment for at-risk patients UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first...
European approval for novel device supporting surgical treatment of lymphedema September 14, 2020 (Union City, CA) – Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first...
Exclusive agreement for Terumo to market and distribute Fibralign’s BioBridge in Japan June 02, 2020 06:00 AM Eastern Daylight Time UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced...